Companies /Healthcare

Kodiak Sciences Inc

NASDAQ: KOD Biotechnology
$91.12
▲ $1.20 (+1.33%) today
Markets closed · 3:50am ET

Fundamentals

Market Cap
$5.7B
EPS (TTM)
$-4.19
52-Week Range
$11 – $96
Street Target
$64.00

About Kodiak Sciences

Kodiak Sciences Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for retinal diseases. Its flagship product, tarcocimab tedromer, is making strides in clinical studies to address conditions like wet age-related macular degeneration and diabetic macular edema. Additionally, Kodiak is exploring treatments for inflammatory retinal diseases and dry AMD with its early-stage candidates. Founded in 2009 and evolving from Oligasis, LLC, Kodiak is based in Palo Alto, California, pushing the boundaries of retinal disease treatment.

KOD Coverage